Document Detail

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
MedLine Citation:
PMID:  15136217     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVES: CD45 is a critical regulator of signaling threshold in immune cells. There are clinical and animal studies suggesting that the CD45-negative phenotype is the phenotype of progressive multiple myeloma (MM). The aims of this study were to confirm this hypothesis and to test the prognostic value of CD45 expression in newly diagnosed MM patients. DESIGN AND METHODS: In a retrospective study of 95 newly diagnosed MM patients treated with high dose therapy we used 4-color flow cytometry to determine CD45 expression and correlated the immunophenotipic data with clinical data. RESULTS: Thirty of 95 patients (31.5%) lacked CD45 expression at diagnosis. The CD45 phenotype significantly affected the overall survival (OS) of the patients, like the most common presenting prognostic parameters analyzed including b-2-microglobulin, age and 14q32 translocations. CD45 negative MM patients had a significantly worse OS than did CD45 positive cases of MM: 28.7% cumulative survival at 4 years, median 42 months vs not reached; p = 0.004. Furthermore, CD45 remained the only parameter adversely affecting OS in multivariate analysis. INTERPRETATION AND CONCLUSIONS: The CD45 negative phenotype could reflect the phenotype of progressive disease in relation to the intrinsic malignancy of the MM clone. Indeed, CD45 negative myeloma cells appear to have a greater capacity to circulate, disseminate and clone as well as being less sensitive to apoptosis.
Philippe Moreau; Nelly Robillard; Herve Avet-Loiseau; Danielle Pineau; Nadine Morineau; Noel Milpied; Jean-Luc Harousseau; Regis Bataille
Related Documents :
20535147 - Primary therapy with single agent bortezomib as induction, maintenance and re-induction...
20010167 - Integrating novel therapies in the transplant paradigm.
6384577 - Aclarubicin in the treatment of multiple myeloma.
20048187 - Bortezomib as induction before autologous transplantation, followed by lenalidomide as ...
3669757 - Human lymphoblastoid interferon for hairy cell leukemia: results from the italian coope...
1612507 - Management of endometrial adenocarcinoma with cervical involvement.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Haematologica     Volume:  89     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-05-11     Completed Date:  2006-04-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  547-51     Citation Subset:  IM    
Department of Clinical Hematology, University Hospital, Nantes, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD45 / analysis,  physiology*
Antineoplastic Agents, Alkylating / administration & dosage
Bone Marrow Cells / immunology
Chromosomes, Human, Pair 14 / genetics
Dose-Response Relationship, Drug
Flow Cytometry
Melphalan / administration & dosage
Middle Aged
Multiple Myeloma / drug therapy*,  genetics,  immunology*
Plasma Cells / immunology
Retrospective Studies
Survival Rate
Translocation, Genetic
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 148-82-3/Melphalan; EC, CD45

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-...
Next Document:  A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in ...